Physician profile
Thomas Vangeem
NPI 1801974779
$831.40
in general payments reported to CMS, 2019-2025
12 companies · $75.82 in 2025
The $75.82 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $128 · 2021: $290 · 2022: $133 · 2024: $45.85 · 2025: $75.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $121.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $239.09 | 2019-2022 | |
| Pfizer INC. | $212.99 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $90.50 | 2024-2025 | Gardasil 9, M-M-R II, Gardasil |
| Myovant Sciences INC. | $69.61 | 2021-2022 | |
| Duchesnay USA Incorporated | $41.53 | 2019 | |
| Therapeuticsmd, INC. | $37.34 | 2019-2020 | |
| Amgen INC. | $31.85 | 2019 | |
| Lilly USA, LLC | $31.17 | 2025 | Mounjaro |
| Allergan, INC. | $21.86 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $21.34 | 2021 | |
| Lupin INC. | $17.81 | 2019 | |
| Amag Pharmaceuticals, INC. | $16.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Vangeem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.